Standout Papers

Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Sev... 2020 2026 2022 2024238
  1. Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis (2020)
    Emma Guttman‐Yassky, Andrew Blauvelt et al. JAMA Dermatology

Immediate Impact

64 standout
Sub-graph 1 of 22

Citing Papers

Tumor-associated macrophages remodel the suppressive tumor immune microenvironment and targeted therapy for immunotherapy
2025 Standout
Atopic dermatitis
2025 Standout
14 intermediate papers

Works of Ramanan Gopalan being referenced

Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis
2020 Standout
Lebrikizumab, a High-Affinity IL-13 Inhibitor, Improves Clinical Manifestations in Moderate-to-Severe Atopic Dermatitis: Primary Results From a Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging, Phase 2b Study
2019

Author Peers

Author Last Decade Papers Cites
Ramanan Gopalan 142 222 76 176 7 309
Jeremias Antinew 95 240 71 171 10 322
Ioanna Maria Dimitriou 89 204 27 178 13 353
Lauren Becker 164 286 50 200 7 365
William D. Boothe 61 286 49 177 7 346
Gareth Muirhead 71 183 64 116 5 285
Hiroshi Komazaki 103 292 96 217 9 360
Marie Morren 35 196 20 126 8 285
Adrian Morris 59 169 17 153 9 259
Rachel Moate 112 251 75 208 5 317
Fiorella Barocci 30 181 29 265 7 306

All Works

Loading papers...

Rankless by CCL
2026